A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...
Nanobiotix S.A. has surged on strong NBTXR3 data, but its sole asset is out-licensed to Johnson & Johnson. Learn more about ...
A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback